Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials

Find Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials Near You

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Adaptive Clinical Study and Open-label Extension Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

The goal of this clinical trial is to learn if drug CB03-154 works to treat ALS in adults. It will also learn about the safety of drug CB03-154. The main questions it aims to answer are: * Does drug CB03-154 have an effect on delaying disease progression, improving function, and prolonging survival in adult ALS patients? * What medical problems do patients have when taking drug CB03-154? Researchers will compare drug CB03-154 to a placebo (a look-alike substance that contains no drug) to see if drug CB03-154 works to treat ALS. Participants (adult ALS patients) will: * Take drug CB03-154 or a placebo every day for 39 weeks (an additional 39 weeks would be required if entering the open-label extension phase). * Visit the clinic approximately every 2-3 months for checkups and tests, and there is also telephone follow-up in between. * Keep a diary of daily medication (CB03-154 or other concomitant medications), and if there are any unplanned medications, the reason (disease or symptoms) also need be recorded.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Agree to follow the treatment plan and trial procedures of this study, and sign the written informed consent form.

• Male or female, aged 18 to 65 years, inclusive.

• The weight of subjects during the screening period must not be less than 45 kg, and the BMI must not be less than 18 kg/m2.

• Diagnosed according to the Revised EI Escorial diagnostic criteria set by the World Federation of Neurology: definite ALS, probable ALS, lab supported probable ALS, or possible ALS.

• Less than or equal to 24 months since ALS symptom onset at Screening, and estimated survival time of ≥1 year as per the Investigator's judgement.

• Forced vital capacity (FVC) \>80% of predicted value for gender, height, and age at Screening.

• Able to swallow oral medication (tablets) at Screening as judged by the investigator.

• For participants taking riluzole: Dose must be stable for at least 4 weeks prior to Screening and participant must be expected to remain on treatment for the duration of the trial. Participants receiving riluzole should maintain the same dose throughout the study.

• Currently not receiving edaravone treatment or is in the schedule of edaravone treatment cycle. Participants receiving edaravone treatment must complete at least one cycle of treatment before the screening visit and continue stable dose edaravone treatment throughout the study.

⁃ Women of childbearing potential (WOCBP) must use an approved highly effective contraception for at least one menstrual cycle before the first dose of the investigational product and for at least 3 months after the last dose of the investigational product. Similarly, men must start using effective contraception before the first dose of the investigational product and continue for at least 3 months after the last dose of the investigational product, with no plans for procreation. Male participants cannot donate sperm for at least 3 months during the trial and after the last dose of the investigational product and female participants cannot donate or freeze eggs during the trial and for at least 3 months after the last dose of the investigational product.

Locations
Other Locations
China
Peking University Third Hospital
RECRUITING
Beijing
Contact Information
Primary
Dongsheng Fan, MD,PhD
dsfan@aliyun.com
+86 10 82265694
Time Frame
Start Date: 2025-10-30
Estimated Completion Date: 2027-10
Participants
Target number of participants: 240
Treatments
Experimental: CB03-154 5mg
Participants will receive CB03-154 5mg and Placebo 10mg orally once daily for 39 weeks.
Experimental: CB03-154 10mg
Participants will receive CB03-154 10mg and Placebo 5mg orally once daily for 39 weeks.
Experimental: CB03-154 15mg
Participants will receive CB03-154 15mg orally once daily for 39 weeks.
Placebo_comparator: Placebo 15mg
Participants will receive Placebo 15mg orally once daily for 39 weeks.
Sponsors
Leads: Shanghai Zhimeng Biopharma, Inc.

This content was sourced from clinicaltrials.gov